Abstract-Atherosclerosis contributes to the development of many cardiovascular diseases, which remain the leading cause of death in developed countries. Atherosclerosis is a chronic inflammatory disease of large and medium sized arteries. It is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Inflammation is a key factor at all stages of atherosclerosis progression. Cells involved in pathogenesis of atherosclerosis were shown to be activated by soluble factors, cytokines, that strongly influence the disease development. Pro inflammatory cytokines accelerate atherosclerosis progression, while anti inflammatory cytokines ameliorate the disease. In this review, we discuss the latest findings on the role of cytokines in the development and progression of atherosclerosis.
CARDIOVASCULAR DISEASES
Cardiovascular diseases (CVDs) remain the leading cause of death in industrially developed countries [1] . The number of CVD related deaths has also been increasing in the developing world. Factors that drive CVD develop ment include hyperlipidemia (lipid and carbohydrate metabolism disorder) caused by obesity or hereditary pre disposition (family hyperlipidemia), arterial hyperten sion, diabetes mellitus, age, smoking, sedentary lifestyle, stress, or a combination of these factors. Atherosclerosis plays a predetermining role in the pathogenesis of the two most common CVDs -cardiac ischemia and cerebrovas cular disease [2] (World Health Organization; http://www.who.int/mediacentre/factsheets/fs317/ru/). For many years, high blood pressure and elevated blood levels of cholesterol have been considered the major fac tors promoting atherosclerosis. However, recent studies have convincingly demonstrated that chronic inflamma tion also plays a key role in the pathogenesis of athero sclerosis [3] .
ROLE OF INFLAMMATION AND IMMUNE CELLS IN ATHEROSCLEROSIS
The arterial wall is composed of three layers: the inner layer -intima, the intermediate layer -media, and the external layer -adventitia. Intima consists of a single layer of endothelial cells, thin basal membrane, and suben dothelial layer of collagen fibers. Media is formed by smooth muscle cells (SMCs) and a network of elastin and collagen fibers. Adventitia is the outer layer and compri sized mostly of loose connective tissue. The atherosclero sis is characterized by the formation of atherosclerotic plaques in subendothelial layer, SMC proliferation, accu mulation of activated immune cells, and thickening of adventitia at the site of plaque formation (figure). Various immune cells are normally present in the arterial wall; however, their number increases significantly during ather osclerosis progression (figure, panels (a) and (b)). Under normal conditions, immune cells migrate into the aortic wall and return to the circulation [4] , thereby "patrolling" the tissue. At early stages of atherosclerosis, high concen tration of low density lipoproteins (LDLs) in the plasma, LDL accumulation in the aortic wall with subsequent LDL oxidation into oxLDLs, and high blood pressure activate endothelial cells, promote the expression of adhesion mol ecules, and facilitate the migration of monocytes into the aortic wall [5] . Monocytes differentiate into macrophages that engulf oxLDLs and convert into lipid filled foam cells. Accumulation of modified LDLs by macrophages activates cytokine production by these cells. Cytokines promote the influx and activation of other inflammatory cells and mediate their retention in the plaque, leading to further accumulation of inflammatory cells in the plaque and surrounding adventitia ( figure, panel (b) ).
As in other tissues, the wall of a healthy artery con tains resident macrophages that originate from the yolk sac during embryonic development [6] . Atherosclerosis is characterized by a high level of local proliferation of both resident and differentiated from monocytes macrophages [7 9 ].
Beside monocytes, other myeloid cells were shown to mediate inflammatory changes in the aortic wall [7, 10 12] . Recent studies have shown an important role of neutrophil extracellular traps (NETs), composed of extra cellular DNA and neutrophil proteins, in the activation of interleukin (IL 1) production and inflammation in athero sclerosis [10] .
Cells of adaptive immunity (T and B lymphocytes) also play an important role in the development of inflam mation in the vessel wall [5] . Different types of T helper (Th) cells have been found in the aortic wall. The number of these cells, state of their activation, and the array of pro duced by them cytokines change along the disease pro gression. The role of Th cells in atherosclerosis will be dis cussed below. B lymphocytes (B1 and B2) are present in both healthy and atherosclerotic aortas. During the devel opment of atherosclerosis, B1 cells perform protective functions by producing antibodies against various lipids, while B2 cells are pathogenic [5, 13] Later stages of atherosclerosis are characterized by so called unresolved inflammation that is maintained by various factors including increased levels of oxLDLs and high blood pressure [14] .
The distinguishing feature of advanced atherosclero sis is progressive accumulation of foam cells in plaques. Foam cells are formed from macrophages because of excessive lipid accumulation by the latter, they cannot leave the plaque and eventually die, mostly via in situ necrosis leading to the formation of the necrotic nucleus. The necrotic nucleus destabilizes the compact structure of the plaque and causes its rapture leading to thrombus formation, which in turn can result in complete vessel blockage and cardiovascular complications, such as myocardial infarction and stroke [15] .
The most commonly used animal models for study ing atherosclerosis are mice with knockout of apo lipoprotein E gene (Apoe -/-) or LDL receptor gene (Ldlr -/-). Mice lacking lipid binding ApoE develop ath erosclerosis spontaneously; the process is exacerbated by a high lipid diet. In Ldlr -/-mice, atherosclerosis is induced by a high lipid diet. In these mice, the absence of LDLR in non hematopoietic cells, namely hepato cytes, is a prerequisite for the development of atheroscle rosis. The Ldlr -/-model has certain advantages and allows bone marrow transplantation from other knock out models.
ROLE OF CYTOKINES IN THE DEVELOPMENT OF ATHEROSCLEROSIS
Cytokines are protein mediators, which participate in many physiological processes and play a key role in inflam mation. Cytokines are a very diverse group of molecules that includes over 100 secreted factors that could be subdi vided into several classes: interleukins (ILs), tumor necro sis factors (TNFs), interferons (IFNs), transforming growth factors (TGFs), colony stimulating factors (CSFs), and various chemokines. Cytokines are produced by T cells, monocytes, macrophages, and platelets, as well as by endothelial cells (ECs), SMCs, and adipocytes, in response to inflammation and other stimuli. An increased production of pro inflammatory cytokines is related to dis ease progression and promotes atherosclerosis [16] . Cytokine induced activation of ECs can cause endotheli um dysfunction accompanied by upregulation of adhesion molecules and chemokines, which promotes migration of immune cells (monocytes, neutrophils, lymphocytes) into atherosclerosis site [17] . Cytokines also affect the function of SMCs by promoting their growth, proliferation, and migration [15] . At later stages of atherosclerosis, pro inflammatory cytokines promote destabilization of athero sclerotic plaques, apoptosis of various cells, and matrix degradation, thereby accelerating plaque breakage and thrombus formation [14, 15] .
For many years, cytokines produced by T helper cells were classified into two groups: cytokines produced by type I T helper cells (Th1) and cytokines produced by type II T helper cells (Th2). Recent studies showed the importance of type 17 T cells (Th17 cells) and regulatory T (Treg) cells in the pathogenesis of various immune dis orders.
The major role of Th1 cytokines is activation of macrophages and T cells; cytokines produced by Th2 cells stimulate humoral response [18] . Th17 cells regulate infiltration and activation of myeloid cells in the inflam mation locus [19] . Treg cells inhibit the activation of all types of T cells and suppress immune responses mediated by T cells [18] (table) .
Type I cytokines. Type I cytokines are produced by Th1 cells (CD4 + T cells) and include interferon gamma (IFN γ) and tumor necrosis factor α (TNF α).
Interferon gamma (IFN γ). CVD patients exhibit increased blood levels of IFN γ [20] . IFN γ production is especially elevated in the atherosclerotic plaque, where IFN γ is produced by Th1 cells (CD4 + cells), cytotoxic T cells (CD8 + cells), and natural killer (NK) cells [21] . IFN γ has been found to act as a pathogenetic factor in atherosclerosis; it promotes inflammatory response by activating macrophages [22] , T lymphocytes [23] , NK cells, B cells, and vascular SMCs [24] . In particular, IFN γ was shown to increase SR A (scavenger receptor A) expression on macrophages, thus, facilitating oxLDL accumulation and foam cell formation [25] . Genetic knocking out of either IFN γ receptor or IFN γ consid erably suppressed inflammation and increased collagen content in the plaque [26] . At the same time, administra tion of exogenous IFN γ promoted the development of atherosclerosis [27] . Inhibition of IFN γ signaling by the administration of soluble mutant IFN γ receptor (sIFN γR) suppressed the inflammation and stabilized athero sclerotic plaques in Apoe -/-mice [28] . Tumor necrosis factor α (TNF α). TNF α is a pro inflammatory cytokine involved in cell homeostasis and immune response regulation [29] . TNF α has been also found to play a key role in the development of atheroscle rosis. It is produced by CD4 + T cells and myeloid cells in the aorta. Atherosclerosis progression always directly cor relates with a local increase in TNF α production in the atherosclerotic plaque and with TNF α level in blood [30] .
Experiments in mice with double knockout of the TNF α (Tnf α -/-) and ApoE (Apoe -/-) genes revealed significant reduction of plaque size in the aortic sinus of Tnf α -/-Apoe -/-mice compared to control Apoe -/-group due to decreased expression of ICAM 1 and VCAM 1 adhesion molecules and monocyte chemotactic protein 1 (MCP 1) [31] . Note, that in rheumatoid arthritis patients predisposed to CVD, anti TNF α therapy decreased the occurrence of CVD events [32] .
Therefore, experimental data obtained from animal models and the analysis of atherosclerosis in humans con vincingly prove the pathogenic role of type I cytokines (IFN γ and TNF α).
Type II cytokines. Type II cytokines are produced by Th2 cells, innate lymphoid cells (ILCs), and eosinophils. The role of several Th2 like cytokines (IL 4, IL 5, and IL 13) has also been investigated in the pathogenesis of atherosclerosis. Early publications suggested that Th2 cells are main producers of type II cytokines. It has been demonstrated that IL 4 and IL 5 participate in athero sclerosis progression by regulating antibody production by B cells. Th2 cells have been considered strictly anti inflammatory, since their action counteracts the func tions of Th1 cells during the development of atheroscle rosis and other vascular disorders. However, a number of studies have demonstrated a possible pathogenic role of cytokines produced by these cells.
Interleukin 4 (IL 4)
. IL 4 regulates differentiation of Th2 cells via STAT6. STAT6 activates GATA3 transcrip tion factor, which promotes T cell differentiation into Th2 cells producing IL 4, IL 5, and IL 13. In athero sclerosis resistant mouse models, production of cytokines is shifted toward type II, suggesting a protective role of these molecules [33] . However, in Ldlr -/-mice, IL 4 deficiency had virtually no effect on the progression of atherosclerosis [34] . Some studies convincingly demonstrated that IL 4, on the contrary, induces inflam mation by acting on endothelial cells and increasing the expression of pro inflammatory mediators, such as cytokines, chemokines, and adhesion molecules (ICAM 1) [35] . IL 4 was also found to induce apoptosis of endothelial cells via activation of caspase 3 signaling pathway, resulting in the endothelial cell dysfunction [36] .
Interleukin 5 (IL 5)/Interleukin 13 (IL 13).
Mouse models studies suggest an antiatherogenic role of IL 5 and IL 13. Indeed, Il 5 -/-Ldlr -/-mice developed more severe atherosclerotic lesions than Ldlr -/-controls [37] . IL 5 was shown to stimulate the production of neutraliz ing antibodies (IgM) against oxLDLs, therefore con tributing to the reduction of atherosclerotic plaque size [37] .
Previous studies addressing the role of IL 13 in ath erosclerosis demonstrated that administartion of recom binant IL 13 stabilized the plaque due to increased con tent of collagen, decreased VCAM 1 dependent recruit ment of monocytes and reduced accumulation of macrophages [38] . It is important to note that IL 13 defi ciency accelerated atherosclerosis development in Ldlr -/-mice and does not affect cholesterol level in the blood [38] . Therefore, IL 13 displays protective properties in atherosclerosis and favorably modulates the morphology of the plaque.
IL 13 and IL 4 act through the same signaling path way (IL 4Rα/IL 13Rα1 and STAT6) and, therefore, have similar functions, such as regulation of B cells, monocytes, dendritic cells, and fibroblasts [39 41 ].
However, some of their functions are differ. For example, IL 13 activates an alternative signal transduction via IL 13Rα2, a receptor that binds exclusively IL 13, and induces the production of transforming growth factor TGFβ in macrophages through the STAT 6 independent pathway, required for collagen biosynthesis in vivo [42] . Overall, the role of Th2 cytokines in atherosclerosis has not been fully elucidated, and, perhaps, is stage depend ent.
Th17 like cytokines. IL 17A belongs to the IL 17 cytokine family and is produced by Th17 cells, γδ T cells, and type 3 ILCs. Th17 lymphocytes synthesize IL 17 (or IL 17A), IL 17F, and IL 17C. Moreover, Th17 lympho cytes can also produce IL 21 and IL 22, which play an important role in the accumulation of macrophages and neutrophils as well as T cell activation [43] . IL 22 is involved in the regulation of the barrier function and microbiome activity in the intestine. Activation of the IL 17 producing cells (Th17 cells and type 3 ILCs) with sub sequent production of Th17 cytokines depends on the RORγτ transcription factor and is regulated by IL 23, IL 6, and IL 1β produced by myeloid and epithelial cells [44, 45] .
Interleukin 17A (IL 17A). Despite the fact that in the past few years the role of IL 17A in atherosclerosis has drawn considerable attention, the function of this cytokine still remains unclear [46] . Many studies described the presence and accumulation of IL 17A producing cells in the aortic wall during atherosclerosis progression [47, 48] . Some reports suggested a protective role of this cytokine. Indeed, knockout of the IL 17A encoding gene (Il17a -/-) in Apoe -/-mice accelerated the production of IFN γ by CD4 + T cells in the spleen, thereby promoting formation of atherosclerotic plaques [49] . In addition, an increased content of macrophages and reduced SMC actin in the plaque fibrous cap in Il17a -/-Apoe -/-mice suggest a potential role of IL 17A, possibly, via IL 17A dependent IFN γ and IL 5 produc tion at the early stages of the disease [50] . Mice lacking the suppressor of cytokine signaling 3 (SOCS3) gene in T cells developed less severe atherosclerosis, which corre lated with an increased production of IL 17A and sug gested indirect protective role of IL 17A [51] . However, the majority of studies revealed a proatherogenic role of this cytokine. Apoe -/-mice with genetic ablation of IL 17A or IL 17A receptor (IL 17RA) were characterized by ameliorated disease due to reduction of chemokine dependent infiltration of monocytes and neutrophils to the aortic intima [52] . Blocking IL 17A by adenovirus produced IL 17 receptor strongly suppressed plaque development in Apoe -/-mice [53] due to the reduction of pro inflammatory molecules expression (IL 6 and gran ulocyte colony stimulating factor, G CSF) and macrophage accumulation in the aortas. Therefore, it has been suggested that IL 17A promotes atherosclerosis by regulating monocyte infiltration into the intima [53] mice decreased expression of VCAM 1 cell adhesion molecule, infiltration of immune cells into the aortic wall, and secretion of pro inflammatory cytokines and chemokines (IL 6, TNF α, CCL5), which altogether suppressed atherosclerosis development [54] . At the same time, administration of recombinant IL 17A promoted the formation of atherosclerotic plaques [55] .
Interleukin 22 (IL 22). IL 22 is produced by activat ed T cells (Th17 cells) and ILCs.
It is involved in tissue regeneration, metabolism regulation, and maintaining of bacterial homeostasis in the intestine [56] . The role of IL 22 in atherosclerosis is poorly investigated.
Recent studies demonstrated a reduction of athero sclerosis plaque burden in Il22 -/-Apoe -/-mice compared to control Apoe -/-group. It was suggested that IL 22 acti vates migration of SMCs from the aortic media to the intima, and therefore promotes plaque development [57] . We found that IL 22 presumably acts as an antiathero genic molecule, possibly, due to its capability to regulate barrier function and microbial activity in the intestine. Our experiments demonstrate that Ldlr -/-mice reconsti tuted with Il22 -/-bone marrow displayed more rapid ath erosclerosis progression than the control group (unpub lished data).
Interleukin 6 (IL 6)/Interleukin 12 (IL 12) cytokine superfamily. Interleukin 6 (IL 6).
Cytokines of this super family are dimeric molecules that signal via dimeric receptor complexes. gp130 receptor chain participates in the formation of some of the receptor complexes of this superfamily [58] .
Interleukin 6 (IL 6) receptor is a heterodimer com posed of IL 6R and gp130. Ligand binding activates STAT1 and STAT3 transcription factors [59] . IL 6 can play either a pro or anti inflammatory role in the patho genesis of various autoimmune disorders. Thus, IL 6 can activate the expression of IL 1 receptor (IL 1RA) antag onist and release of soluble TNF α receptor, which strongly suppresses IL 1 and TNF α activities, respec tively [60] . It was suggested that the role of IL 6 in ather osclerosis depends on the stage of disease and can be either pathogenic or protective [59, 61] .
Earlier studies demonstrated that introduction of recombinant IL 6 results in a two fold increase in the area of atherosclerotic lesions in Apoe -/-mice, suggesting the pro inflammatory role of this cytokine [62] . At the same time, 24 week old Apoe -/-mice lacking the IL 6 gene (Il6 -/-Apoe -/-) were characterized by accelerated plaque formation associated with decreased collagen content, reduced IL 10 production, and reduced accumulation of inflammatory cells in the lesions [63] . However, in anoth er study, 9 week old Il6 -/-Apoe -/-mice displayed no such differences when compared to the control group [64] .
Recent studies revealed that IL 6 signals not only through the classical cell surface IL 6 receptor, but also through its soluble form (sIL 6R). The IL 6/sIL 6R complex binds directly to gp130 that is present on the sur face of almost all cells in an organism and activates pro inflammatory response. This process was named trans signaling [65] . On the other hand, tissue regeneration and anti inflammatory activity of this cytokine are mediated by the classical IL 6R signaling pathway. It was shown that administration of soluble gp130 (sgp130) that specif ically inhibits the IL 6/sIL 6R complex but does not affect the classical IL 6R dependent signaling pathway considerably suppressed atherosclerosis in Ldlr -/-mice [66] .
Interleukin 12 (IL 12)/Interleukin 23 (IL 23) . IL 12 is an important regulator of Th1 cells, whereas IL 23 controls differentiation and functions of Th17 cells and type 3 ILCs [67, 68] . IL 12 is a heterodimer composed of p35 and p40 subunits, while IL 23 is composed of p19 and p40 subunits. This complicates the interpretation of in vivo phenotypes of mice with the knockouts of individ ual subunits. The observed positive correlation between CVD and the levels of IL 12 and IL 23 in patients' blood suggests proatherogenic function of these cytokines [69] . IL 12 has been shown to act as a proatherogenic mole cule in animal models, since the size of atherosclerotic lesions in Il12 -/-Apoe -/-mice was considerably smaller than in the control group [70] . In addition, the adminis tration of recombinant IL 12 promoted atherosclerosis [71] .
Although the role of IL 17A, a cytokine induced by IL 23, is well known, the effects of IL 23 itself in athero sclerosis still have to be investigated in genetically modi fied animal models. Our studies showed a protective role of this cytokine in atherosclerosis. Ldlr -/-mice trans planted with Il23 -/-or Il23r -/-bone marrow had signifi cantly larger atherosclerotic lesions (unpublished data).
Interleukin 27 (IL 27)/Interleukin 35 (IL 35). IL 27 is a heterodimer composed of p28 and Ebi3 subunits. The Ebi3 subunit is common for IL 27 and IL 35 cytokines [59] . IL 27 is an anti inflammatory cytokine with a broad range of activities that affect multiple cell types [72] . IL 27 suppresses the activation of CD4 + T cells, since IL 27 receptor deficient mice demonstrate increased accumulation and activation of Th1 and Th17 CD4 + T cells in the aorta and increased production of IL 17A and IL 17A regulated chemokines (e.g. MCP 1) with subsequent accumulation of different types of myeloid cells [73] . IL 27 also inhibits lipid accumulation in macrophages, thereby suppressing formation of foam cells [74] .
IL 35 is a heterodimer composed of p35 and Ebi3 subunits. This anti inflammatory cytokine is produced by Tregs [75] . IL 35 regulates the expression of anti inflam matory cytokines, facilitates the development of Tregs, inhibits CD4 + T cell response, suppresses the progression of inflammatory and autoimmune disorders [76] . Ebi3 and p35 subunits were found in atherosclerotic aorta [77] , and deletion of the Ebi3 subunit gene promotes the dis ease in atherosclerosis prone mouse models [74] . Recent studies showed that IL 35 inhibits lipopolysaccharide (LPS) induced acute inflammation in vascular wall by suppressing the expression of VCAM 1 by endothelial cells due to inactivation of the mitogen activated protein kinase (MAPK) signaling pathway [78] . Therefore, IL 27 and IL 35 display pronounced antiatherogenic properties and might be used as agents for anti atherosclerosis ther apy in the future.
Interleukin 1 (IL 1) cytokine family. The IL 1 fami ly includes 11 proteins, such as IL 1α, IL 1β, IL 1 recep tor antagonist (IL 1RA), IL 18, IL 33 (ligand of the membrane bound ST2L receptor), and other less investi gated cytokines [79] .
Interleukin 1 (IL 1). IL 1α and IL 1β are pro inflammatory cytokines produced by myeloid cells. Secretion of IL 1 family cytokines and expression of their receptors are increased in atherosclerotic aortas [80] . IL 1β is an essential factor of Th17 cell differentiation [81] that can exacerbate inflammation in the vascular wall. Experiments in mouse models confirmed proatherogenic properties of IL 1α and IL 1β that are involved into the upregulation of adhesion molecules expression by endothelial cells as well as macrophage activation [80, 82] . At the same time, IL 1RA displays endogenous anti inflammatory properties since IL 1RA is a potent inhibitor of IL 1 signaling pathways. The production of IL 1β in atherosclerosis depends on the activation of the NLRP3 inflammasome caused by lysosomal distruction by accumulated in macrophages cholesterol crystals. The receptor complex composed of CD36, TLR4, and TLR6 is required for binding and internalization of modified lipoproteins (oxLDLs) as well as for the activation of NLRP3 and subsequent IL 1β production. Knockout of any component of the CD36/TLR4/TLR6 complex con siderably decreases the production of IL 1β active form and reduces atherosclerotic plaque burden [83] . The pro duction of IL 1α is stimulated by fatty acids via NLRP3 independent pathway [84] . IL 1α, IL 1β, or IL 1R defi ciency strongly reduces atherosclerosis progression [80, 84, 85] . Recombinant IL 1RA (or IL 1RA based drug Anakinra) suppresses inflammation in atherosclerosis, whereas IL 1RA deficincy significantly exacerbates the disease [86] . The administartion of recombinant IL 1RA into Apoe -/-mice [87] , or IL 1RA overexpression in Ldlr -/- [88] or Apoe -/-mice, notably suppress plaque burden [89] . On the contrary, IL 1RA knockout C57BL/6J mice fed a high fat diet tended to accumulate foam cells in the aortic wall and, thus, had accelerated disease [88] .
Interleukin 18 (IL 18) . IL 18 is a pro inflammatory cytokine; its expression is elevated in atherosclerotic plaques [90] . IL 18 production is also elevated in patients with myocardium infarction and diabetes mellitus [91] . IL 18 administration in Apoe -/-mice accelerates athero sclerosis [92] , whereas overexpression of the IL 18 bind ing protein, an endogenous inhibitor of IL 18, strongly supresses the disease [93] . It was suggested that the proatherogenic effect of IL 18 is mediated by IFN γ, since atherosclerosis progression is diminished in IFN γ deficient Apoe -/-mice [92] . The administration of recombinant IL 18 into Apoe -/-mice upregulates IFN γ production in the lesions and promotes the disease pro gression [94] .
Interleukin 33 (IL 33) . IL 33 exhibits strong immunomodulatory properties [95] . It regulates the pro duction of Th2 cytokines (IL 4, IL 5, and IL 13) by Th2 cells, type 2 ILCs, and eosinophils. The administration of recombinant IL 33 upregulates IL 4, IL 5 and IL 13 production as well as immunoglobulins A, E, and G1, while suppresses IFN γ, thereby stimulating the protec tive response and suppressing atherosclerosis develop ment [96] . The administration of soluble IL 33 receptor (ST2L) strongly reduces atherosclerosis in mouse models [96] . Moreover, IL 33 is a potent inhibitor of oxLDL uptake and foam cell formation [97] .
Interleukin 10 (IL 10) cytokine family. [99] . These cytokines stimulate various protective immune mechanisms and are essential for maintanence of tissue homeostasis [99] .
Interleukin 10 (IL 10). IL 10 plays a key role in the regulation of innate and adaptive immune responses by suppressing the activation of Th1 cells and macrophages and activating antibody production by B cells [100] . IL 10 is produced by myeloid and Treg cells. Experiments in mouse models showed that genetic inactivation of IL 10 accelerates atherosclerosis due to increased infiltration of inflammatory cells and production of pro inflammatory cytokines in atherosclerotic lesions [101 103 ]. Therefore, IL 10 is a key pro inflammatory cytokine in pathogenesis of atherosclerosis.
Interleukin 20 (IL 20) subfamily. Cytokines of the IL 20 subfamily are produced by both non immune and immune cells, including myeloid cells and lymphocytes [98] . IL [104] . Recent studies demonstrated that IL 19 deficiency causes vascular SMCs (VSMC) activation and pro inflammatory mole cules production, including IL 1β, TNF α, and MCP 1. Beside VSMC activation, IL 19 also controls endothelial cells activation, since elevated adhesion molecules espression was found in Il19 -/-atherosclerosis prone mice [105] . Taken together these data suggest that IL 19 is a potent suppressor of atherosclerosis development, which controls VSMC migration, proliferation and pro inflammatory molecules expression [106] .
The role of IL 20 is not completely understood. This cytokine is produced mostly by epithelial cells and adipocytes [90] . Both IL 20 and its receptor IL 20R1/IL 20R2 can be detected in human atherosclerotic plaques. In mouse models, the administration of recom binant IL 20 exacerbates the disease in Apoe -/-mice [107] , suggesting a pathogenic role of this cytokine.
Transforming growth factor TGFβ β. Three isoforms of TGFβ have been described -TGFβ1, TGFβ2, and TGFβ3. All isoforms have been implicated into the regu lation of various biological processes by engaging three types of cell surface receptors known as types I, II, and III. All subsets of cells in our body, including epithelial, endothelial, hematopoietic, and connective tissues, express TGFβ and its receptor [108] . TGFβ regulates cell proliferation and differentiation and therefore is critical for embryonic development. It is essential for supporting normal structure of blood vessel wall [109] . TGFβ also plays an important role in the regulation of immune cells, since it inhibits proliferation, activation, and differentia tion of Th1 and Th2 cells. It is also required for differen tiation of Tregs [16] . In atherosclerosis, TGFβ plays anti inflammatory and antiatherogenic role [110] . Neutralization [111] or genetic ablation [112] of TGFβ promotes the development of atherosclerosis in Apoe -/-mice and facilitates the recruitment of pro inflammatory macrophages and T cells into the site of inflammation. At the same time, TGFβ was shown to decrease collagen content in the aorta. Therefore, TGFβ is a key antiatherogenic cytokine required for Tregs differentia tion, which in turn suppresses T cells.
Inflammation plays an important role at all stages of atherosclerosis development -from attracting immune cells and atherosclerotic plaque formation to its rupture. Chronic inflammation in the aortic wall is caused by dys lipidemia, innate and adaptive immune responses and is mediated by various pro inflammatory cytokines. The balance between pro and anti inflammatory cytokines is the major factor that determines the stability of athero sclerotic plaque.
Experimental data obtained from mouse models of atherosclerosis has shown that inhibition of pro inflam matory cytokines suppresses atherosclerosis development and progression. For example, anti TNF α therapy decreases the risk of CVD in patients with rheumatoid arthritis. At the same time, all attempts to use clinically anti inflammatory TGFβ and IL 10 have failed, in part due to incomplete understanding of the function of these cytokines in atherosclerosis. Therefore, discovering and studying functions of new atheroprotective cytokines can BIOCHEMISTRY (Moscow) Vol. 81 No. 11 2016 significantly contribute to the development of new approaches for anti atherosclerosis therapy. One of the potential strategies in the development of new treatment methods could be a suppression of inflammatory immune response by shifting the balance toward anti inflammato ry mediators to achieve the stabilization of atherosclerot ic plaque.
